Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
1.280
-0.120 (-8.57%)
At close: Feb 21, 2025, 4:00 PM
1.281
0.00 (0.04%)
After-hours: Feb 21, 2025, 7:50 PM EST
Moleculin Biotech Employees
Moleculin Biotech had 18 employees as of December 31, 2023. The number of employees decreased by 1 or -5.26% compared to the previous year.
Employees
18
Change (1Y)
-1
Growth (1Y)
-5.26%
Revenue / Employee
n/a
Profits / Employee
-$1,675,000
Market Cap
3.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MBRX News
- 9 days ago - Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Benzinga
- 9 days ago - Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - PRNewsWire
- 9 days ago - Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) - PRNewsWire
- 11 days ago - Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - PRNewsWire
- 26 days ago - Moleculin Participates in Virtual Investor "What This Means" Segment - PRNewsWire
- 6 weeks ago - Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 - PRNewsWire
- 2 months ago - Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model - PRNewsWire
- 3 months ago - New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PRNewsWire